British officials sparked anger and confusion today with a sudden decision to block private companies from carrying out Covid-19 finger-prick antibody tests for the public.
The Medicines and Healthcare products Regulatory Agency (MHRA) has told firms offering to test blood samples people take themselves from finger-pricks to ‘temporarily stop providing this service’.
Until then, people had been able to buy mail order kits for upwards of £69 from online pharmacies to find out if they have already had the coronavirus.
The tests have been around for weeks online, with Superdrug even having to suspend its because of overwhelming demand.
They involve taking blood and looking for signs of past infection, which is indicated by the presence of antibodies from the immune system.
But the Government is thought to have become jittery about the prospect of people finding out they might be immune to the virus and ignoring lockdown rules.
The move, which officials deny is a ban and say is merely guidance, led to critics accusing the Government of ‘making it up as they go’. One top scientist said it showed a ‘lack of foresight’.
MHRA officials met this morning to discuss the subject and are carrying out a review of the tests involved.
It only concerns tests which rely on people taking their own blood from their finger, not ones which use professional samples of vein blood.
It is unclear how many of these have been sold already but it is understood to affect thousands of people. Superdrug admitted only that it had received ‘strong demand’.
The issue has only just come to light because officials noticed a surging number of these home tests being offered within the last few days, MailOnline understands.
Abbott, one of the manufacturers of a Government validated test which is being used by Superdrug, is furious that its tests are being used with self-sampled blood, which was not its intended use. It has sold 800,000 of the tests to the NHS already.
The MHRA’s messaging has caused confusion because companies bought the same tests approved by the Government – which will be used on NHS and care workers from this week – but uses them in a different way, which makes them less accurate.
It is not believed to be linked to a report issued yesterday by the US’s Centers for Disease Control & Prevention, which suggested that even highly accurate antibody tests may be wrong up to 50 per cent of the time when used for an uncommon virus.
Antibody tests use blood samples to look for signs of past infection and, if positive, show that somebody may have some degree of immunity to a disease. However, scientists still do not fully understand how much immunity people develop to Covid-19, if any
Dr Simon Clarke, a cellular microbiology expert at the University of Reading, said taking the decision this late in the day was ‘really odd’.
At least half a dozen companies have already bought antibody tests and are selling them en masse to members of the public, many of whom are now unable to get results despite having paid for a private service.
Dr Clarke said the Government was probably panicking that people receiving positive antibody results might believe they were immune to Covid-19 and get brave about breaking lockdown rules.
He told MailOnline: ‘This is really odd. At least one of the tests validated by the Government is commercially available.
‘Why they’re telling people not to use them; they don’t want people to be assuming that they’ve had the virus and are immune.
‘Them not wanting to think that way is probably right… but this should have been put to bed earlier.’
He said that taking the decision now shows ‘a lack of foresight that getting it wrong could cause problems’.
At least two laboratories are known to have stopped processing as a result of the ‘guidance’ from the MHRA.
Professor Karol Sikora, a former World Health Organization cancer chief, took antibody testing into his own hands at the Rutherford Cancer Centres where he is medical director.
He told this website: ‘In Britain the testing is appalling. There seems to be no strategy and it changes by the day. They’re making it up as they go…
‘It’s another failure. We shouldn’t have got to this point in the pandemic and not had a properly worked out testing strategy both for the virus and antibodies. It should have been sorted out at the beginning.
‘The real problem is, if you’ve got this in the post and never done it before, the chances of you screwing it up are high – it’s just the way these things are designed. And people are nervous about pricking their fingers anyway. So there’s a lot of inconsistency.’
The finger-prick tests have never been approved by the Government because they use a different type of blood to that which official tests have been validated on.
In the lab the tests use blood taken directly from a patient’s veins, while the home tests may use blood from capillaries, which are tiny vessels carrying oxygenated blood through the skin.
After noticing rising numbers of pharmacies offering the home finger-prick tests the MHRA is now cracking down on these firms by urging them to stop.
The tests remain legal and it is not clear whether the Government has any legal powers to stop the companies doing the testing anyway, but officials fear the results could be unreliable.
People who bought the tests complained on Twitter that companies should not have been selling them in the first place if they weren’t approved.
One user, Maneesh Juneja, tweeted: ‘I wonder if consumers like me who paid £69 for a covid-19 antibody test where they have already got a result back, will refund consumers now that the tests with finger prick blood sample method have to be validated by the MHRA?’
Another, Helen Ashby, said she had ordered a test and tweeted at online pharmacy Thriva: ‘Really shouldn’t have taken my order then!’
Ben Read said: ‘Stop selling coronavirus antibody kits until you are approved to sell them. Been given the run around for a test I purchased last week, supposedly blocked by MHRA guidance from April. Pretty deceitful.’
People who have bought tests have shown on Twitter that they were unhappy to be sold something not approved by the Government
The Medicines and Healthcare products Regulatory Agency (MHRA) told MailOnline last night: ‘Patient safety and public health are our main priorities and it is in the interests of everyone for antibody tests to be as reliable and meaningful as they can be.
‘There are several UK providers of testing services who offer Covid-19 antibody testing using a fingerprick sample of capillary blood collected in a small container.
‘We are asking all providers of laboratory-based Covid-19 antibody testing services using capillary blood collected by a fingerprick to temporarily stop providing this service until home collection of this sample type has been properly validated for use with these laboratory tests.
‘Use of unvalidated sample types may lead to unreliable results and as such we are working closely with the service providers, laboratories and test manufacturers to resolve the regulatory and patient safety issues.
‘People who have purchased one of these sampling kits, and received an antibody test result, should not consider the result to be reliable and should not take any action on it.
‘This does not affect rapid point of care tests or laboratory tests performed using venous blood.’
The way antibody tests work is that a blood sample is taken from a patient, either by medical professional or by themselves, and that is posted off to a lab.
There, qualified technicians analyse the blood to look for antibodies for the coronavirus, which are immune system substances created when someone is infected with the virus.
People then receive a result in which the presence of antibodies – a positive result – indicates they have already had the virus, or the absence that they have not.
The lab analysis stage is now being blocked by the MHRA because the tests are being used with blood taken by the patient themselves.
The best-known company providing antibody tests, Superdrug, voluntarily stopped issuing its tests last week because of immense demand, so it could get through all the ordered samples.
It did not confirm whether the MHRA rule had affected its service.
A spokesperson said: ‘We have been contacted by the MHRA and are in ongoing discussions with them about Covid-19 laboratory-based testing services and the updated guidance provided by Abbott.
‘We are also contacting all our Covid-19 antibody testing service customers today to provide further information about the quality and safety of our Covid-19 antibody laboratory-based testing service. We are updating them on our current position together with inviting them to contact us directly if they’d like further information or if they have any questions or concerns.
Lloyds Pharmacy is also believed to have been affected by the decision but did not confirm this.
Andy Sloman, a managing director at the company, said: ‘We are working closely with our partners and regulators and have taken the decision to temporarily pause the LloydsPharmacy Online Doctor COVID-19 antibody testing service pending further guidance.
‘The health and safety of customers is our top priority, particularly during such a difficult and uncertain time.
‘We are following the developing advice and guidance on COVID-19 antibody tests from the government and medical professionals closely.’
Professor Ian Jones, a virologist at Reading university, said: ‘In general I am in favour of freedom of choice as long as there is full information given on the reliability of the test performed.
‘After all, you can buy any number of totally useless products sold under the vitamin or “immune health” type banner and the Government does nothing.
‘It’s worth noting that part of Germany’s success in dealing with the epidemic was because of a commercial testing drive, in that case for active infections.
‘The problem with centralisation is that it cannot cope with the numbers and that any teething troubles affect all samples.
‘A disseminated system at least avoids this. It seems to me the issue is lack of accurate information about which kits are acceptable and which providers are offering them. Then people can choose.’